Search details
1.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood
; 140(2): 112-120, 2022 07 14.
Article
in English
| MEDLINE | ID: mdl-35427411
2.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Article
in English
| MEDLINE | ID: mdl-34407545
3.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med
; 381(5): 432-443, 2019 08 01.
Article
in English
| MEDLINE | ID: mdl-31365801
4.
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 21(10): 1317-1330, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32866432
Results
1 -
4
de 4
1
Next >
>>